Maria Libera Ascierto

Excited to see this work now online. Congrats to all Providence SJCI team involved 👏 linkedin.com/posts/maria-li…

Excited to see this paper out from my former team at Providence Health Center in Santa Monica. Very good work and congratulations to All 🎉👏💪🏻nature.com/articles/s4427…

@ProfRScolyerMIA @JWilmott38 @inespiresilva @amenzies9 @MattCarlino @syd_health @CPC_usyd @SHPartners @SydneyResearch @SydneyCatalyst @PathologyRCPA This is fantastic news. Very happy for you

Fantastic news!!!!!! Amazingly, my latest MRI brain scan shows no recurrence 10 months since my #glioblastoma presented with a seizure in #Poland. Median time to recurrence is 6 months. I’m extremely hopeful that the novel #neoadjuvant combination #immunotherapy I’ve had & the scientific changes we demonstrated in my tumour post versus pre immunotherapy are being translated into clinical benefit! I’d be thrilled & very proud if this novel approach makes a difference for me & future #brain #cancer patients. Thanks @ProfGLongMIA for devising & facilitating this superb approach & other members of multidisciplinary team including the @MelanomaAus team & other specialists @Dr_Brindha, Helen Wheeler, Michael Back & many others. Well done also to our @MelanomaAus translation research team including @HelenRizos! Special thanks for the ongoing support of my wife Katie, 3 kids Em, Matt & Luce, bro Mark, @subbie & many other family & friends! @SydneyLHD @Sydney_Uni @MelanomaAus @ausoftheyear

@Gino_K_In_USC @kmargolin @arivanderw @GeoffGibney @LutzkyJose @lab_ito @FrancesChowMD @DoctorZada @LHwangMD Congratulations for leading this very important effort. Thanks to you and Caris team for letting me be part of it.

See below for our transcriptomic study on melanoma brain metastases ⁦@kmargolin⁩ ⁦@arivanderw⁩ ⁦⁦@GeoffGibney⁩ ⁦@MLAscierto⁩ ⁦@LutzkyJose⁩ ⁦@lab_ito⁩ ⁦@FrancesChowMD⁩ ⁦@DoctorZada⁩ ⁦@LHwangMD⁩ nature.com/articles/s4169…

@DrBetofMDPhD @RZappasodi @WCM_MeyerCancer Go @RZappasodi !!!

The 4PD-1 hi story keeps growing. Fantastic presentation by @RZappasodi from @WCM_MeyerCancer on Th1 vs Tfh polarization as a mediator of 4PD-1hi-induced ICB resistance.

Congratulations to Dr Kim Margolin, for this very much deserved award. Thank you, Dr Margolin for all what you have done for patients and for the immunotherapy field.

@HTawbi_MD @DrSapnaPatel Congrats !

Congrats @DrSapnaPatel on leading and presenting this Phase I study using a novel SMARCA4/SMARCA2 inhibitor (FHD-286) in metastatic uveal melanoma. Congrats on continuing to lead the way in this tough disease.

Wonderful melanoma Symposium with great talks. Thanks to the organizers for the invitation linkedin.com/posts/saint-jo…

@rbryanbell @BernardAFox Happy bday Bernie!

Happy birthday, to one of my “oldest” friends, and amongst the finest human beings on the planet, ⁦@BernardAFox⁩! Your noble work continues to inspire and enlighten, shining brighter than ever. Looking forward to many more years together in the fight to #FinishCancer.

Proud and honored to speak at the 2nd Melanoma Symposium in Santa Monica this coming Saturday, April 29th 2023- Register below and plan to attend! Melanoma Symposium - Saint John’s Cancer Institute (saintjohnscancer.org)

Next generation immuno-oncology strategies: Unleashing NK cells activity, is now available online. Thanks to the team for this solid work and happy reading. mdpi-res.com/d_attachment/c…

A #Melanoma Symposium bit.ly/36Gvpn1 Join @EssnerRick @kmargolin @MLAscierto Sat April 30 @FairmontHotels Santa Monica @vernonsondak @jasonlukemd @alliegrossman @DrSancy @drsapnapatel @drtrevanfischer @stevenkolkermd & Drs.Ron Korn, Dave Hoon, Patrick Ott

PRACTICE CHANGING news in #uveal #melanoma. @FDAOncology approved tebentafusp for advanced uveal melanoma. This is huge- first drug to show OS benefit in this patient population! Thanks to the patients who participated in this trial and congrats to the investigators! @OncoAlert

From the Nov. issue: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mutations in non-small-cell #lungcancer patients and is reversed by STAT3 knockdown. bit.ly/3l3fzHA @nabendu71 @MLAscierto et. al @AstraZeneca

Congrats to @Immunocore for @NEJM publication Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. Proud to be part of this program and its success for our patients #clinicaltrials @angelesclinic nejm.org/doi/full/10.10…

I cannot be more honored and proud to lead this journey at SJCI linkedin.com/posts/maria-li…

Can't escape T cell exhaustion in the latest @NatImmunol, with a triptych of papers from: @DebattamaSen @EJohnWherry, Georg Lauer and a great N&V explainer from @Hazemghoneim11 nature.com/ni/volumes/22/… [1/n]

Priceless tips shared by key immunotherapy leaders during WIN leadership Institute workshop. sitcancer.org/education/win?…. #leadershipdevelopment #coaching #emotionalintelligence #immunotherapy

Now online in @CD_AACR: Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional #STK11 mutations in NSCLC and is reversed by #STAT3 knockdown, by @nabendu71 @MLAscierto and colleagues @AstraZeneca #immunotherapy cancerdiscovery.aacrjournals.org/content/early/…

One Post- Doctoral Fellowship and one Flow Cytometry Specialist position are immediately available at St John’s Cancer Institute. Join my team to support the advancement of Immunology, Cancer Immunotherapy, Biomarker Discovery #immunotherapy,#immunology,#jobopening,